In pediatrics, a phase 1/2 clinical trial open in Europe and some U.S. centers is currently recruiting MLL-r infant ALL and FLT3-mutant AML patients to receive midostaurin as a single agent, with a primary outcome of determining the maximally tolerated dose (MTD). The gene discussed is KMT2A; the disease is acute myeloid leukemia.